T1	MajorClaim 1 145	Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.
T2	MajorClaim 146 262	Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.
T3	Premise 1688 1883	The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
T4	Premise 1884 2049	The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).
T5	Premise 2050 2170	The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
T6	Premise 2171 2349	Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
T7	Premise 2350 2519	The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
T8	Claim 2520 2702	The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
T9	MajorClaim 2703 2859	Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
R1	Support Arg1:T3 Arg2:T8	
R2	Support Arg1:T4 Arg2:T8	
R3	Support Arg1:T5 Arg2:T8	
R4	Support Arg1:T6 Arg2:T8	
R5	Support Arg1:T7 Arg2:T8	
R6	Support Arg1:T8 Arg2:T9	
